GEN Exclusives

More »

GEN News Highlights

More »
Jan 23, 2007

Medarex and Compugen Partner on Mab-Based Therapeutics in Oncology and Autoimmune Diseases

  • Medarex and Compugen are partnering to develop Mab-based therapeutics for oncology and autoimmune diseases.
    Compugen expects to utilize its antibody-target discovery engine to identify drug targets. Medarex plans to develop fully human antibodies against these targets using its UltiMAb Human Antibody Development System®.

    The collaboration also provides that Compugen may independently pursue diagnostic applications involving certain antibodies and targets.

    Under the terms of the agreement, Medarex and Compugen plan to share discovery, development, and commercialization responsibilities as well as revenues generated from the sale of any therapeutic products resulting from this collaboration.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

GEN Poll

More » Poll Results »

New Drugs for Ebola

Do you think that biopharma companies should not have to go through the normal drug approval process in order to get potential life-saving therapies to Ebola patients more quickly?